| Product Code: ETC9964668 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Duchenne Muscular Dystrophy Treatment Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Duchenne Muscular Dystrophy Treatment Market - Industry Life Cycle |
3.4 United States (US) Duchenne Muscular Dystrophy Treatment Market - Porter's Five Forces |
3.5 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.6 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume Share, By Therapy, 2021 & 2031F |
3.7 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United States (US) Duchenne Muscular Dystrophy Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about Duchenne Muscular Dystrophy (DMD) among healthcare professionals and patients |
4.2.2 Advances in research and development leading to the introduction of innovative treatment options |
4.2.3 Rising investments in healthcare infrastructure and facilities dedicated to DMD treatment |
4.3 Market Restraints |
4.3.1 High cost associated with DMD treatments and therapies |
4.3.2 Limited availability of approved drugs for DMD treatment |
4.3.3 Stringent regulatory requirements for drug approval and market entry |
5 United States (US) Duchenne Muscular Dystrophy Treatment Market Trends |
6 United States (US) Duchenne Muscular Dystrophy Treatment Market, By Types |
6.1 United States (US) Duchenne Muscular Dystrophy Treatment Market, By Treatment Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Treatment Type, 2021- 2031F |
6.1.3 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Molecular-Based Therapies, 2021- 2031F |
6.1.4 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Steroid Therapy, 2021- 2031F |
6.1.5 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United States (US) Duchenne Muscular Dystrophy Treatment Market, By Therapy |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Exon Skipping Approach, 2021- 2031F |
6.2.3 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Mutation Suppression, 2021- 2031F |
6.2.4 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Dystrophin-Targeted Therapies, 2021- 2031F |
6.3 United States (US) Duchenne Muscular Dystrophy Treatment Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.3.4 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United States (US) Duchenne Muscular Dystrophy Treatment Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Home Healthcare, 2021- 2031F |
6.4.4 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.5 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.5 United States (US) Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.4 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 United States (US) Duchenne Muscular Dystrophy Treatment Market Import-Export Trade Statistics |
7.1 United States (US) Duchenne Muscular Dystrophy Treatment Market Export to Major Countries |
7.2 United States (US) Duchenne Muscular Dystrophy Treatment Market Imports from Major Countries |
8 United States (US) Duchenne Muscular Dystrophy Treatment Market Key Performance Indicators |
8.1 Average age of diagnosis for DMD patients |
8.2 Number of clinical trials for DMD treatments in progress |
8.3 Patient adherence rate to prescribed treatment regimens |
8.4 Rate of hospital readmissions for DMD patients |
8.5 Average time to market for new DMD treatment options |
9 United States (US) Duchenne Muscular Dystrophy Treatment Market - Opportunity Assessment |
9.1 United States (US) Duchenne Muscular Dystrophy Treatment Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.2 United States (US) Duchenne Muscular Dystrophy Treatment Market Opportunity Assessment, By Therapy, 2021 & 2031F |
9.3 United States (US) Duchenne Muscular Dystrophy Treatment Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 United States (US) Duchenne Muscular Dystrophy Treatment Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 United States (US) Duchenne Muscular Dystrophy Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United States (US) Duchenne Muscular Dystrophy Treatment Market - Competitive Landscape |
10.1 United States (US) Duchenne Muscular Dystrophy Treatment Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Duchenne Muscular Dystrophy Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here